Probi AB has invested approximately NZD 9 million in newly issued shares in Blis Technologies Ltd. In connection with the investment, Blis Technologies and Probi AB have signed a licensing and distribution agreement which means that Probi will manufacture Blis bacterial strains and offer these to Probi's customers around the world. The companies will furthermore collaborate in research and development.